Cargando…
Impact of evergreening on patients and health insurance: a meta analysis and reimbursement cost analysis of citalopram/escitalopram antidepressants
BACKGROUND: "Evergreening" refers to the numerous strategies whereby owners of pharmaceutical products use patent laws and minor drug modifications to extend their monopoly privileges on the drug. We aimed to evaluate the impact of evergreening through the case study of the antidepressant...
Autores principales: | Alkhafaji, Ali A, Trinquart, Ludovic, Baron, Gabriel, Desvarieux, Moïse, Ravaud, Philippe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3520785/ https://www.ncbi.nlm.nih.gov/pubmed/23167972 http://dx.doi.org/10.1186/1741-7015-10-142 |
Ejemplares similares
-
Rise of escitalopram and the fall of citalopram
por: Cavanah, Luke R., et al.
Publicado: (2023) -
Adjustment for reporting bias in network meta-analysis of antidepressant trials
por: Trinquart, Ludovic, et al.
Publicado: (2012) -
Impact of Reporting Bias in Network Meta-Analysis of Antidepressant Placebo-Controlled Trials
por: Trinquart, Ludovic, et al.
Publicado: (2012) -
The Influence of Anti-Infective Periodontal Treatment on C-Reactive Protein: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Demmer, Ryan T., et al.
Publicado: (2013) -
Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients
por: Bhattacharyya, Sudeepa, et al.
Publicado: (2019)